Startle response related genes

Medical Hypotheses

Volumn 77, Issue 4, 2011, Pages 685-691

  Zhang, Lei ^a   Hu, Xian Zhang ^a   Li, He ^a   Li, Xiaoxia ^a   Smerin, Stanley ^a   Benedek, David M ^a   Ursano, Robert ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM BINDING PROTEIN; CATECHOL METHYLTRANSFERASE; GEPHYRIN; GLYCINE RECEPTOR; GLYCINE RECEPTOR SUBUNIT ALPHA 1; GLYCINE RECEPTOR SUBUNIT BETA; GLYCINE TRANSPORTER 2; PROTEIN P11; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER LINKED PROMOTER REGION; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ALLELE; ANXIETY; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CHROMOSOME 11; CHROMOSOME 5Q; DEPRESSION; DNA POLYMORPHISM; EMOTIONALITY; ENDOCYTOSIS; EXOCYTOSIS; FEAR; GENE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HYPEREKPLEXIA; LIFE EVENT; MEDLINE; MEMORY DISORDER; MUSCLE HYPERTONIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STARTLE REFLEX; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANIMALS; ANNEXIN A2; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; GENETIC VARIATION; HUMANS; RECEPTORS, GLYCINE; S100 PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STARTLE REACTION;

ANIMALIA;

EID: 80052619957     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.07.018     Document Type: Article

References (135)

1. Davis M., Gendelman D.S., Tischler M.D., Gendelman P.M. A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci 1982, 2:791-805.
2. Castellote J.M., Kumru H., Queralt A., Valls-Sole J. A startle speeds up the execution of externally guided saccades. Exp Brain Res 2007, 177:129-136.
3. Hoffman H.S., Ison J.R. Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 1980, 87:175-189.
4. Cromwell H.C., Klein A., Mears R.P. Single unit and population responses during inhibitory gating of striatal activity in freely moving rats. Neuroscience 2007, 146:69-85.
5. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992, 49:206-215.
6. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001, 156:234-258.
7. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199:331-388.
8. Swerdlow N.R., Light G.A., Cadenhead K.S., Sprock J., Hsieh M.H., Braff D.L. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 2006, 63:1325-1335.
9. Duncan E., Szilagyi S., Schwartz M., Kunzova A., Negi S., Efferen T., et al. Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol. Psychiatry Res 2003, 120:1-12.
10. Groves P.M., Thompson R.F. Habituation: a dual-process theory. Psychol Rev 1970, 77:419-450.
11. Grillon C., Morgan C.A., Davis M., Southwick S.M. Effect of darkness on acoustic startle in Vietnam veterans with PTSD. Am J Psychiatry 1998, 155:812-817.
12. Quednow B.B., Schmechtig A., Ettinger U., Petrovsky N., Collier D.A., Vollenweider F.X., et al. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biol Psychiatry 2009, 66:614-620.
13. Quednow B.B., Kuhn K.U., Mossner R., Schwab S.G., Schuhmacher A., Maier W., et al. Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms. Biol Psychiatry 2008, 64:434-437.
14. Kang H.C., Jeong You S., Jae Chey M., Sam Baik J., Kim J.W., Ki C.S. Identification of a de novo Lys304Gln mutation in the glycine receptor alpha-1 subunit gene in a Korean infant with hyperekplexia. Mov Disord 2008, 23:610-613.
15. Brauer D., Strobel A., Hensch T., Diers K., Lesch K.P., Brocke B. Genetic variation of serotonin receptor function affects prepulse inhibition of the startle. J Neural Transm 2009, 116:607-613.
16. Stark K.L., Burt R.A., Gogos J.A., Karayiorgou M. Analysis of prepulse inhibition in mouse lines overexpressing 22q11.2 orthologues. Int J Neuropsychopharmacol 2009, 1-7.
17. Levin R., Heresco-Levy U., Bachner-Melman R., Israel S., Shalev I., Ebstein R.P. Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition. Psychoneuroendocrinology 2009, 34:901-908.
18. Lee H.F., Tsai C.R., Chi C.S., Chang T.M., Lee H.J. Aromatic l-amino acid decarboxylase deficiency in Taiwan. Eur J Paediatr Neurol 2009, 13:135-140.
19. Roussos P., Giakoumaki S.G., Bitsios P. A risk PRODH haplotype affects sensorimotor gating, memory, schizotypy, and anxiety in healthy male subjects. Biol Psychiatry 2009, 65:1063-1070.
20. Hirzel K., Muller U., Latal A.T., Hulsmann S., Grudzinska J., Seeliger M.W., et al. Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice identifies Zn(2+) as an essential endogenous modulator of glycinergic neurotransmission. Neuron 2006, 52:679-690.
21. Roussos P., Giakoumaki S.G., Rogdaki M., Pavlakis S., Frangou S., Bitsios P. Prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism. Psychol Med 2008, 38:1651-1658.
22. Roussos P., Giakoumaki S.G., Bitsios P. The dopamine D(3) receptor Ser9Gly polymorphism modulates prepulse inhibition of the acoustic startle reflex. Biol Psychiatry 2008, 64:235-240.
23. Pauli P., Conzelmann A., Mucha R.F., Weyers P., Baehne C.G., Fallgatter A.J., et al. Affect-modulated startle reflex and dopamine D4 receptor gene variation. Psychophysiology 2010, 47:25-33.
24. Ryan S.G., Dixon M.J., Nigro M.A., Kelts K.A., Markand O.N., Terry J.C., et al. Genetic and radiation hybrid mapping of the hyperekplexia region on chromosome 5q. Am J Hum Genet 1992, 51:1334-1343.
25. Brody S.A., Geyer M.A. Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotox Res 2004, 6:79-90.
26. Gregory M.L., Guzauskas G.F., Edgar T.S., Clarkson K.B., Srivastava A.K., Holden K.R. A novel GLRA1 mutation associated with an atypical hyperekplexia phenotype. J Child Neurol 2008, 23:1433-1438.
27. Lonsdorf T.B., Weike A.I., Nikamo P., Schalling M., Hamm A.O., Ohman A. Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. Psychol Sci 2009, 20:198-206.
28. Dulawa S.C., Hen R., Scearce-Levie K., Geyer M.A. Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl) 1997, 132:125-134.
29. Armbruster D., Moser D.A., Strobel A., Hensch T., Kirschbaum C., Lesch K.P., et al. Serotonin transporter gene variation and stressful life events impact processing of fear and anxiety. Int J Neuropsychopharmacol 2009, 12:393-401.
30. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66:2621-2624.
31. Heils A., Teufel A., Petri S., Seemann M., Bengel D., Balling U., et al. Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect 1995, 102:247-254.
32. Wendland J.R., Martin B.J., Kruse M.R., Lesch K.P., Murphy D.L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006, 11:224-226.
33. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002, 297:400-403.
34. Glatt C.E., Freimer N.B. Association analysis of candidate genes for neuropsychiatric disease: the perpetual campaign. Trends Genet 2002, 18:307-312.
35. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
36. Munafo M.R., Lingford-Hughes A.R., Johnstone E.C., Walton R.T. Association between the serotonin transporter gene and alcohol consumption in social drinkers. Am J Med Genet B Neuropsychiatr Genet 2005, 135B:10-14.
37. Schinka J.A., Busch R.M., Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 2004, 9:197-202.
38. Sen S., Burmeister M., Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004, 127B:85-89.
39. Heinz A., Braus D.F., Smolka M.N., Wrase J., Puls I., Hermann D., et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005, 8:20-21.
40. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005, 8:828-834.
41. Brocke B., Armbruster D., Muller J., Hensch T., Jacob C.P., Lesch K.P., et al. Serotonin transporter gene variation impacts innate fear processing: acoustic startle response and emotional startle. Mol Psychiatry 2006, 11:1106-1112.
42. Jacobs N., Kenis G., Peeters F., Derom C., Vlietinck R., van Os J. Stress-related negative affectivity and genetically altered serotonin transporter function: evidence of synergism in shaping risk of depression. Arch Gen Psychiatry 2006, 63:989-996.
43. Eley T.C., Sugden K., Corsico A., Gregory A.M., Sham P., McGuffin P., et al. Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 2004, 9:908-915.
44. Grabe H.J., Lange M., Wolff B., Volzke H., Lucht M., Freyberger H.J., et al. Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. Mol Psychiatry 2005, 10:220-224.
45. Kendler K.S., Kuhn J.W., Vittum J., Prescott C.A., Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 2005, 62:529-535.
46. Taylor S.E., Way B.M., Welch W.T., Hilmert C.J., Lehman B.J., Eisenberger N.I., et al. Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. Biol Psychiatry 2006, 60:671-676.
47. Wilhelm K., Mitchell P.B., Niven H., Finch A., Wedgwood L., Scimone A., et al. Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry 2006, 188:210-215.
48. Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R., et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 1999, 21:434-439.
49. Tunbridge E.M., Bannerman D.M., Sharp T., Harrison P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci 2004, 24:5331-5335.
50. Lewis C.D., Gebber G.L., Larsen P.D., Barman S.M. Long-term correlations in the spike trains of medullary sympathetic neurons. J Neurophysiol 2001, 85:1614-1622.
51. Sesack S.R., Hawrylak V.A., Guido M.A., Levey A.I. Cellular and subcellular localization of the dopamine transporter in rat cortex. Adv Pharmacol 1998, 42:171-174.
52. Matsumoto M., Weickert C.S., Beltaifa S., Kolachana B., Chen J., Hyde T.M., et al. Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology 2003, 28:1521-1530.
53. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase cognition and psychosis: Val158Met and beyond. Biol Psychiatry 2006, 60:141-151.
54. Lachman H.M., Morrow B., Shprintzen R., Veit S., Parsia S.S., Faedda G., et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 1996, 67:468-472.
55. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004, 75:807-821.
56. Blasi G., Mattay V.S., Bertolino A., Elvevag B., Callicott J.H., Das S., et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci 2005, 25:5038-5045.
57. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001, 98:6917-6922.
58. Winterer G., Egan M.F., Kolachana B.S., Goldberg T.E., Coppola R., Weinberger D.R. Prefrontal electrophysiologic " noise" and catechol-O-methyltransferase genotype in schizophrenia. Biol Psychiatry 2006, 60:578-584.
59. Winterer G., Musso F., Vucurevic G., Stoeter P., Konrad A., Seker B., et al. COMT genotype predicts BOLD signal and noise characteristics in prefrontal circuits. Neuroimage 2006, 32:1722-1732.
60. Barnett J.H., Jones P.B., Robbins T.W., Muller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 2007, 12:502-509.
61. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003, 60:889-896.
62. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002, 159:652-654.
63. Nicodemus K.K., Kolachana B.S., Vakkalanka R., Straub R.E., Giegling I., Egan M.F., et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet 2007, 120:889-906.
64. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005, 6:521-532.
65. Domschke K., Freitag C.M., Kuhlenbaumer G., Schirmacher A., Sand P., Nyhuis P., et al. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. Int J Neuropsychopharmacol 2004, 7:183-188.
66. McGrath M., Kawachi I., Ascherio A., Colditz G.A., Hunter D.J., De Vivo I. Association between catechol-O-methyltransferase and phobic anxiety. Am J Psychiatry 2004, 161:1703-1705.
67. Olsson C.A., Anney R.J., Lotfi-Miri M., Byrnes G.B., Williamson R., Patton G.C. Association between the COMT Val158Met polymorphism and propensity to anxiety in an Australian population-based longitudinal study of adolescent health. Psychiatr Genet 2005, 15:109-115.
68. Olsson C.A., Byrnes G.B., Anney R.J., Collins V., Hemphill S.A., Williamson R., et al. COMT Val(158)Met and 5HTTLPR functional loci interact to predict persistence of anxiety across adolescence: results from the Victorian Adolescent Health Cohort Study. Genes Brain Behav 2007, 6:647-652.
69. Woo J.M., Yoon K.S., Choi Y.H., Oh K.S., Lee Y.S., Yu B.H. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase. J Psychiatr Res 2004, 38:365-370.
70. Enoch M.A., Xu K., Ferro E., Harris C.R., Goldman D. Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatr Genet 2003, 13:33-41.
71. Lang U.E., Bajbouj M., Sander T., Gallinat J. Gender-dependent association of the functional catechol-O-methyltransferase Val158Met genotype with sensation seeking personality trait. Neuropsychopharmacology 2007, 32:1950-1955.
72. Reuter M., Ott U., Vaitl D., Hennig J. Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene. J Cogn Neurosci 2007, 19:401-408.
73. Reuter M., Schmitz A., Corr P., Hennig J. Molecular genetics support Gray's personality theory: the interaction of COMT and DRD2 polymorphisms predicts the behavioural approach system. Int J Neuropsychopharmacol 2006, 9:155-166.
74. Stein M.B., Fallin M.D., Schork N.J., Gelernter J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology 2005, 30:2092-2102.
75. Pooley E.C., Fineberg N., Harrison P.J. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol Psychiatry 2007, 12:556-561.
76. Diatchenko L., Slade G.D., Nackley A.G., Bhalang K., Sigurdsson A., Belfer I., et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
77. Smolka M.N., Schumann G., Wrase J., Grusser S.M., Flor H., Mann K., et al. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005, 25:836-842.
78. Smolka M.N., Buhler M., Schumann G., Klein S., Hu X.Z., Moayer M., et al. Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry 2007, 12:307-317.
79. Drabant E.M., Hariri A.R., Meyer-Lindenberg A., Munoz K.E., Mattay V.S., Kolachana B.S., et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 2006, 63:1396-1406.
80. McNaughton N., Gray J.A. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000, 61:161-176.
81. Tijssen M.A., Vergouwe M.N., van Dijk J.G., Rees M., Frants R.R., Brown P. Major and minor form of hereditary hyperekplexia. Mov Disord 2002, 17:826-830.
82. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006, 311:77-80.
83. Zhang L., Li H., Su T.P., Barker J.L., Maric D., Fullerton C.S., et al. p11 is up-regulated in the forebrain of stressed rats by glucocorticoid acting via two specific glucocorticoid response elements in the p11 promoter. Neuroscience 2008, 153:1126-1134.
84. Su T.P., Zhang L., Chung M.Y., Chen Y.S., Bi Y.M., Chou Y.H., et al. Levels of the potential biomarker p11 in peripheral blood cells distinguish patients with PTSD from those with other major psychiatric disorders. J Psychiatr Res 2009, 43:1078-1085.
85. Santamaria-Kisiel L., Rintala-Dempsey A.C., Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006, 396:201-214.
86. Anisman H., Du L., Palkovits M., Faludi G., Kovacs G.G., Szontagh-Kishazi P., et al. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psychiatry Neurosci 2008, 33:131-141.
87. Zhang L., Su T.P., Choi K., Maree W., Li C.T., Chung M.Y., et al. P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res 2010.
88. Czyrak A., Mackowiak M., Chocyk A., Fijal K., Gadek-Michalska A., Wedzony K. 8-OHDPAT-induced disruption of prepulse inhibition in rats is attenuated by prolonged corticosterone treatment. Neuropsychopharmacology 2003, 28:1300-1310.
89. Ebstein R.P., Israel S., Lerer E., Uzefovsky F., Shalev I., Gritsenko I., et al. Arginine vasopressin and oxytocin modulate human social behavior. Ann NY Acad Sci 2009, 1167:87-102.
90. Armbruster D., Mueller A., Strobel A., Kirschbaum C., Lesch K.P., Brocke B. Influence of functional tryptophan hydroxylase 2 gene variation and sex on the startle response in children, young adults, and older adults. Biol Psychol 2010, 83:214-221.
91. Swerdlow N.R., Platten A., Hanlon F.M., Martinez Z.A., Printz M.P., Auerbach P. Sensitivity to sensorimotor gating-disruptive effects of apomorphine in two outbred parental rat strains and their F1 and N2 progeny. Neuropsychopharmacology 2003, 28:226-234.
92. Swerdlow N.R., Shoemaker J.M., Auerbach P.P., Pitcher L., Goins J., Platten A. Heritable differences in the dopaminergic regulation of sensorimotor gating. II. Temporal, pharmacologic and generational analyses of apomorphine effects on prepulse inhibition. Psychopharmacology (Berl) 2004, 174:452-462.
93. Feifel D., Melendez G., Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine a neurotensin agonist but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 2004, 29:731-738.
94. Buckwalter M.S., Testa C.M., Noebels J.L., Camper S.A. Genetic mapping and evaluation of candidate genes for spasmodic, a neurological mouse mutation with abnormal startle response. Genomics 1993, 17:279-286.
95. MacLusky N.J., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F., et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000, 141:752-762.
96. Becker L., Hartenstein B., Schenkel J., Kuhse J., Betz H., Weiher H. Transient neuromotor phenotype in transgenic spastic mice expressing low levels of glycine receptor beta-subunit: an animal model of startle disease. Eur J Neurosci 2000, 12:27-32.
97. Hong L.E., Wonodi I., Stine O.C., Mitchell B.D., Thaker G.K. Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry 2008, 63:17-23.
98. Tijssen M.A., Shiang R., van Deutekom J., Boerman R.H., Wasmuth J.J., Sandkuijl L.A., et al. Molecular genetic reevaluation of the Dutch hyperekplexia family. Arch Neurol 1995, 52:578-582.
99. Plappert C.F., Pilz P.K. The acoustic startle response as an effective model for elucidating the effect of genes on the neural mechanism of behavior in mice. Behav Brain Res 2001, 125:183-188.
100. Gomeza J., Ohno K., Hulsmann S., Armsen W., Eulenburg V., Richter D.W., et al. Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality. Neuron 2003, 40:797-806.
101. Dai H., Okuda T., Sakurai E., Kuramasu A., Kato M., Jia F., et al. Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: a study in H1 receptor gene knockout mice. Psychopharmacology (Berl) 2005, 183:285-293.
102. Koch M., Kling C., Becker C.M. Increased startle responses in mice carrying mutations of glycine receptor subunit genes. Neuroreport 1996, 7:806-808.
103. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19:3248-3257.
104. Cui C., Booker T.K., Allen R.S., Grady S.R., Whiteaker P., Marks M.J., et al. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci 2003, 23:11045-11053.
105. Turnock-Jones J.J., Jennings C.A., Robbins M.J., Cluderay J.E., Cilia J., Reid J.L., et al. Increased expression of the NR2A NMDA receptor subunit in the prefrontal cortex of rats reared in isolation. Synapse 2009, 63:836-846.
106. van den Buuse M., Wischhof L., Lee R.X., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice. enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 2009, 12:1383-1393.
107. Bannon A.W., Seda J., Carmouche M., Francis J.M., Norman M.H., Karbon B., et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000, 868:79-87.
108. Husum H., Termeer E., Mathe A.A., Bolwig T.G., Ellenbroek B.A. Early maternal deprivation alters hippocampal levels of neuropeptide Y and calcitonin-gene related peptide in adult rats. Neuropharmacology 2002, 42:798-806.
109. Caldwell H.K., Stephens S.L., Young W.S. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry 2009, 14:190-196.
110. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat 2009, 5:433-449.
111. Jones K.R., Reichardt L.F. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA 1990, 87:8060-8064.
112. Maisonpierre P.C., Le Beau M.M., Espinosa R., Ip N.Y., Belluscio L., de la Monte S.M., et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991, 10:558-568.
113. Matsumoto T., Rauskolb S., Polack M., Klose J., Kolbeck R., Korte M., et al. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 2008, 11:131-133.
114. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
115. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
116. Russo-Neustadt A.A., Beard R.C., Huang Y.M., Cotman C.W. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience 2000, 101:305-312.
117. Xu Y., Ku B., Tie L., Yao H., Jiang W., Ma X., et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006, 1122:56-64.
118. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003, 54:70-75.
119. Okamoto T., Yoshimura R., Ikenouchi-Sugita A., Hori H., Umene-Nakano W., Inoue Y., et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1185-1190.
120. Gorgulu Y., Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull 2009, 80:158-162.
121. Taylor S.M. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT 2008, 24:160-165.
122. Duncan L.E., Hutchison K.E., Carey G., Craighead W.E. Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. J Affect Disord 2009, 115:215-219.
123. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
124. Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004, 24:4401-4411.
125. Montag C., Weber B., Fliessbach K., Elger C., Reuter M. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psychol Med 2009, 39:1831-1839.
126. Matsuo K., Walss-Bass C., Nery F.G., Nicoletti M.A., Hatch J.P., Frey B.N., et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 2009, 34:1904-1913.
127. Chen Q.Y., Chen Q., Feng G.Y., Wan C.L., Lindpaintner K., Wang L.J., et al. Association between the brain-derived neurotrophic factor (BDNF) gene and schizophrenia in the Chinese population. Neurosci Lett 2006, 397:285-290.
128. Bath K.G., Lee F.S. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006, 6:79-85.
129. Yu H., Wang Y., Pattwell S., Jing D., Liu T., Zhang Y., et al. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci 2009, 29:4056-4064.
130. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007, 17:165-170.
131. Lanktree M., Squassina A., Krinsky M., Strauss J., Jain U., Macciardi F., et al. Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:945-951.
132. Chen L., Lawlor D.A., Lewis S.J., Yuan W., Abdollahi M.R., Timpson N.J., et al. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:814-821.
133. Cattaneo A., Bocchio-Chiavetto L., Zanardini R., Marchina E., Bellotti D., Milanesi E., et al. BDNF Val66Met polymorphism and protein levels in amniotic fluid. BMC Neurosci 2010, 11:16.
134. Choi S.H., Li Y., Parada L.F., Sisodia S.S. Regulation of hippocampal progenitor cell survival, proliferation and dendritic development by BDNF. Mol Neurodegener 2009, 4:52.
135. Gatt J.M., Nemeroff C.B., Dobson-Stone C., Paul R.H., Bryant R.A., Schofield P.R. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009, 14:681-695.